Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Temozolomide 6Radiotherapy 4Irinotecan 3lutetium Lu 177 dotatate 2Nivolumab 2Carboplatin 2sonidegib 1sodium thiosulfate 1silmitasertib 1poly ICLC 1plerixafor 1olaparib 1gallium Ga 68 dotatate 1etoposide phosphate 1entrectinib 1dinutuximab 1bempegaldesleukin 1adavosertib 1abemaciclib 1Vincristine 1Vascular Endothelial Growth Factor A 1Vaccines 1Triiodothyronine 1TPI-287 1Surgical Procedures, Operative 1Radiation 1Peripheral Blood Stem Cell Transplantation 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1Microarray Analysis 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Medulloblastoma × silmitasertib × Clear all
NCT03904862 2025-10-30

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Pediatric Brain Tumor Consortium

Phase 1/2 Terminated
21 enrolled
CNS

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡